BioSpace News Archive

A novel MRI-guided procedure that uses therapeutic ultrasound effectively treats prostate cancer with minimal side effects, according to a new study presented at the annual meeting of the Radiological Society of North America.

Amarin Corporation plc announced that the European Medicines Agency has validated the marketing authorization application seeking approval for icosapent ethyl as a treatment to reduce the risk of cardiovascular events in high-risk patients who have their cholesterol levels controlled with statin treatment, but have elevated triglycerides,135 mg/dL or above, and other cardiovascular risk factors.

Axonics Modulation Technologies, Inc. announced Health Canada approved the use of full-body magnetic resonance imaging using 1.5 and 3 Tesla MRI scanners for patients implanted with the Axonics r-SNM System.

Dyno Therapeutics founders and collaborators demonstrate machine-guided AAV capsid engineering with the potential to transform gene therapy

CureVac’s GMP I, II and III Combined Production Suite Scales Up Capacity to Meet All Preclinical, Clinical and Early Launch Needs for Proprietary and Partnered Programs

Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced that the European Medicines Agency (EMA) has validated the company’s Marketing Authorization Application (MAA) for OTL-200,

BioArctic AB announced that presentations related to BAN2401 will be given at the 12th Clinical Trials on Alzheimer’s Disease conference to be held December 4-7 in San Diego, California, USA.

Artificial intelligence and advanced visualization leader, TeraRecon, unveiled multiple new AI-enabled workflow subscription offerings which are designed to deliver key AI insights in the form of dashboard views that physicians can engage with and verify as they generate advanced measurements and reports.

Concord Medical Services Holdings Limited, a specialty hospital management group and an operator of the network of radiotherapy and diagnostic imaging centers in China, announced the resignation of Mr. Shang Yan Chuang as director of the Company.

18 month project in collaboration with University of Leeds and Medicines Discovery Catapult will deliver a new compound for treatment of thrombosis